semaglutide 7.2 mg clinical trial once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled Impact of patient characteristics on

The most common issues include nausea, vomiting, and diarrhea

Factors influencing progress include: Starting Weight: Higher starting weights may result in more rapid initial losses

Metabolic Benefits: Its hormonal effects enhance fat oxidation and reduce fat storage, aligning with our centers focus on promoting metabolic health

Semaglutide mimics this hormone and works in three ways: Reduces appetite by acting on hunger and satiety centres in the brain Slows gastric emptying food moves out of your stomach more slowly, so you feel full longer Reduces calorie intake as a combined result of the above Unlike some older weight-loss drugs, Wegovy doesnt stimulate the central nervous system and doesnt cause dependency